Trials / Completed
CompletedNCT06648824
Study of How Mitapivat Affects Midazolam Blood Levels in Healthy Participants
A Phase 1, Open-label, One-Sequence Crossover Study to Assess the Effect of Mitapivat on the Pharmacokinetics of the CYP3A Substrate (Midazolam) in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Agios Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
The primary purpose of this study is to assess the effect of mitapivat on the single oral dose pharmacokinetics (PK) of midazolam in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mitapivat | Oral tablets |
| DRUG | Midazolam | Oral syrup |
Timeline
- Start date
- 2024-10-17
- Primary completion
- 2024-12-03
- Completion
- 2024-12-03
- First posted
- 2024-10-18
- Last updated
- 2025-01-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06648824. Inclusion in this directory is not an endorsement.